Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alt801
2. Glxc-26955
3. 2538014-94-5
Molecular Weight | 3790 g/mol |
---|---|
Molecular Formula | C178H270N38O53 |
XLogP3 | -7.4 |
Hydrogen Bond Donor Count | 51 |
Hydrogen Bond Acceptor Count | 57 |
Rotatable Bond Count | 131 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 1500 |
Heavy Atom Count | 269 |
Formal Charge | 0 |
Complexity | 8720 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 34 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Altimmune Completes End-Of-Phase 2 Meeting with FDA for Pemvidutide
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
November 07, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide for MASH
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
September 30, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Altimmune Weight Loss Drug Shows Reduced Muscle Loss in Trials
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
March 28, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
November 29, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
October 26, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
September 12, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
August 01, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of d...
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
March 21, 2023
Details:
ALT-801 (pemvidutide), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
December 20, 2022
Details:
ALT-801 (pemvidutide) is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ALT-801
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-801 (pemvidutide) is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Product Name : ALT-801
Product Type : Peptide
Upfront Cash : Not Applicable
October 28, 2022
ABOUT THIS PAGE